EXCEL-II Stent Vesus EXCEL Stent to Treat the Patients With de Novo Coronary Artery Lesions.

Coronary Artery Disease Clinical Trial

— CREDIT-II  

Official title:

A Prospective Multicenter Randomized Trial to Assess the Safety and Effectiveness of EXCEL-II vs. EXCEL Sirolimus Eluting Stent for the Treatment of Patients With de Novo Coronary Artery Lesions .( CREDIT II Trial )

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02057978
• Other study ID #: CREDIT-II-131105
• Status: Completed
• Start date: December 8, 2013
• Est. completion date: December 25, 2019

Study information

• Verified date: April 2023
• Source: JW Medical Systems Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

The purpose of this Randomized Study to evaluate the safety and efficacy of the Excel-II DES compared to the EXCEL DES in the treatment of patients with de novo coronary artery lesions.

Description:

The primary end point is to observe in-stent late lumenn loss after 9 months of the stent implantation. This study is based on non-inferior assumption (vs. EXCEL-II V EXCEL Stent), requring all of end points reach statictic significance. Quality assurance plan that addresses data validation and registry procedures, including any plans for site monitoring and auditing. Data checks to compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry. Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources (e.g., medical records, paper or electronic case report forms, or interactive voice response systems). Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information if used and normal ranges if relevant. Standard Operating Procedures to address registry operations and analysis activities, such as patient recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. Plan for missing data to address situations where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results Statistical analysis plan describing the analytical principles and statistical techniques to be employed in order to address the primary and secondary objectives, as specified in the study protocol or plan.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 419
• Est. completion date: December 25, 2019
• Est. primary completion date: October 20, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion criteria:

1.18yrs=Age=75yrs . 2.stability and unstable angina pectoris (AP), chronic myocardial infarction (OMI) or confirmed myocardial ischemia; 3.De novo lesion at native coronary artery(Up to two target lesions). 4.Lesion length =32mm. 5.RVD 2.5mm~4.0mm. 6.DS%=70% by visual test. 7.Coronary artery bypass surgery (coronary artery bypass grafting) patients. 8.Subjects are willing to follow the specified requirements follow-up. 9.To understand the purpose of the trial and willing to sign informed consent and accept clinical follow-up.

Exclusion Criteria:

1. AMI within 7 days.

2. CTO (TIMI 0), the left main lesion, ostial lesion and transplant vascular lesions, the bifurcation lesion (reference collateral blood vessel diameter of 2.5 mm or higher), stent restenosis lesions and to deal with three pathological changes;

3. Severe calcified lesion unable to predilate.

4. The distortion of the stent was hampered by lesions.

5. NYHA=? or LVEF<40%.

6. Prior PCI within 1 year.

7. Pregnancy or lactation, and planning pregnancy or lactation.

8. Subjects have bleeding tendency or blood coagulation dysfunction or PCI contraindications, or anticoagulant therapy taboo or can't continue to take DAPT at least 1 year.

9. There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (< 1 year).

10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy.

11. Serious liver and kidney function are not complete subject(ALT and AST were three times greater than the upper limit of normal).

12. Before enrolling to participate in other clinical trials and not reached the primary endpoint.

13. Non-compliant subject and could not finish the trial in accordance with the requirements of the subjects.

Related Conditions & MeSH terms

• Arterial Occlusive Diseases
• Arteriosclerosis
• Cardiovascular Diseases
• Coronary Artery Disease
• Coronary Disease
• Heart Diseases
• Ischemia
• Myocardial Ischemia
• Vascular Diseases

Intervention

Procedure:
• EXCEL DES implatation
Implant DES for CAD cases
• EXCEL-II DES implantation
Implant DES for CAD cases

Locations

Country	Name	City	State
China	Shenyang Northern Hospital	Shenyang	Liaoning

Sponsors (1)

Lead Sponsor	Collaborator
JW Medical Systems Ltd

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	9 months in-stent late lumen loss	To observe in-stent late lumen loss after 9 months of stent implantation	9 months
Secondary	9-m in-segment diameter restenosis rate	9-m in stent, proximal stent edge, the distal edge segment defined in the restenosis rate, 9-m after lesions within the segment late lumen loss percentage and the diameter of the restenosis degree	9 months
Secondary	Device success rates , lesion success rates , clinical success rates Device, lesion, & clinical success rates Device, lesion, & clinical success rates Target Lesion Failure	Device oriented composite of cardiac death, MI, or ischemia-driven TLR at 1m, 6m, 12m,18m and annually up to 5 yrs	1m,6m,9m,12m,18m and annually to 5years
Secondary	Rate of stent thrombosis	Definite and probable stent thrombosis according to ARC defination	1m,6m,9m,12m,18m and annually up to 5 yrs